# Lorundrostat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lorundrostat

> The PDUFA target action date for lorundrostat, sponsored by Mineralys Therapeutics, Inc. (MLYS), is December 22, 2026, for hypertension in combination with other antihypertensive drugs. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the lorundrostat PDUFA date?

The PDUFA target action date for lorundrostat, sponsored by Mineralys Therapeutics, Inc. (MLYS), is December 22, 2026, for hypertension in combination with other antihypertensive drugs. Status: scheduled. Press release filed with the SEC (EX-99): "- Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 -" Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/lorundrostat)

Source: Press release filed with the SEC (EX-99), accession 0001933414-26-000142, https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/lorundrostat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | lorundrostat |
| Codes | MT-4129 |
| Sponsor | Mineralys Therapeutics, Inc. (MLYS) https://sec-api.dev/companies/mlys/catalysts |
| Indications | [hypertension in combination with other antihypertensive drugs](https://sec-api.dev/indications/hypertension-in-combination-with-other-antihypertensive-drugs), hypertension in participants with hypertension and comorbid ckd, [hypertension](https://sec-api.dev/indications/hypertension), moderate to severe obstructive sleep apnea and hypertension, hypertension and comorbid ckd, [Obstructive Sleep Apnea](https://sec-api.dev/indications/obstructive-sleep-apnea) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Q1 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-12, last confirmed 2025-02-12.
- SEC Form 10-K (accession 0001933414-25-000009): "Other indications: We anticipate initiating our Phase 2 clinical trial (Explore-OSA) in the first quarter of 2025, which is planned to evaluate the safety and efficacy of lorundrostat 50 mg QD in approximately 40 subjects with moderate-to-severe OSA." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000009/mlys-20241231.htm

### 1H 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001933414-24-000056): ""We are excited that the two pivotal trials from this program are fully enrolled and on track to deliver topline data during the first half of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys3q248kex991.htm

### March 10, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-02-04, last confirmed 2025-05-12.
- SEC Form 8-K (accession 0001628280-25-011459): "On March 10, 2025, the Company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN." https://www.sec.gov/Archives/edgar/data/1933414/000162828025011459/mlys-20250310.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000006): "- Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/mlys202502048kex991.htm
- SEC Form 10-Q (accession 0001933414-25-000058): "Randomization of 60 subjects was completed in the first quarter of 2025, and topline data from this trial is anticipated in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000058/mlys-20250331.htm
- SEC Form 10-K (accession 0001933414-25-000009): "Randomization of 60 subjects was completed in the first quarter of 2025, and topline data from this trial is anticipated in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000009/mlys-20241231.htm

### March 29, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000026): "Following the recently announced positive topline data from both Advance-HTN and Launch-HTN pivotal trials, detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys202503318kex991.htm
- SEC Form 10-K (accession 0001933414-25-000009): "Randomization of 285 subjects was completed in the fourth quarter of 2024, and topline data from this trial is anticipated in March 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000009/mlys-20241231.htm
- SEC Form 10-Q (accession 0001933414-24-000057): "Randomization of subjects was completed in the fourth quarter of 2024, and topline data from this trial is anticipated in March 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341424000057/mlys-20240930.htm
- SEC Form 10-K (accession 0001933414-25-000009): "Randomization of 1,083 subjects was completed in the fourth quarter of 2024, and topline data from this trial is anticipated in mid first half of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000009/mlys-20241231.htm
- SEC Form 10-Q (accession 0001933414-24-000057): "Randomization of subjects was completed in the fourth quarter of 2024, and topline data from this trial is anticipated to be available in mid first half of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341424000057/mlys-20240930.htm

### June 17, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-02-12, last confirmed 2026-03-12.
- SEC Form 8-K (accession 0001933414-25-000070): "On June 17, 2025, the Company announced positive topline data from its Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in subjects with hypertension and comorbid CKD." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000070/mlys-20250617.htm
- SEC Form 10-K (accession 0001933414-26-000056): "In June 2025, we announced positive topline data from our Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in addition to an SGLT2 inhibitor for the treatment of hypertension in participants with hypertension and comorbid CKD." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm
- SEC Form 10-Q (accession 0001933414-25-000142): "In June 2025, we announced positive topline data from our Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in addition to a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of hypertension in participants with hypertension and comorbid CKD." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000142/mlys-20250930.htm
- SEC Form 10-Q (accession 0001933414-25-000090): "In June 2025, we announced positive topline data from our Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in addition to a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of hypertension in participants with hypertension and comorbid CKD." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000090/mlys-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000057): "•Explore-CKD Phase 2 Trial - Enrollment has been completed and topline data are anticipated in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000008): "•Explore-CKD Phase 2 Trial - Enrollment completed and topline data is anticipated in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000008/mlysfy248kex991.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-05-12, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000139): "These findings for lorundrostat will provide the foundation for an NDA submission which we anticipate submitting near the end of 2025 or during the first quarter of 2026," stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000057): "With the success of our two pivotal trials, we are working toward submitting our new drug application with a pre-NDA meeting with the FDA anticipated in the fourth quarter of 2025," stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys2025q18kex991.htm

### December 17, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Obstructive Sleep Apnea; Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06785454 (A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." https://clinicaltrials.gov/study/NCT06785454

### December 22, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: hypertension in combination with other antihypertensive drugs.
- First seen 2026-03-12, last confirmed 2026-11-04.
- SEC Form 10-K (accession 0001933414-26-000056): "We submitted our NDA for lorundrostat to the FDA on December 22, 2025, and we have not yet received regulatory approval from the FDA or from other regulatory jurisdictions." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm
- SEC Form 10-Q (accession 0001933414-26-000144): "We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- SEC Form 10-Q (accession 0001933414-26-000114): "We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm
- SEC prospectus (424B) (accession 0001628280-26-040216): "We submitted our new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000162828026040216/myls-finalprospectusjune20.htm
- SEC Form 10-Q (accession 0001933414-26-000084): "We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000084/mlys-20260331.htm
- SEC Form 10-K (accession 0001933414-26-000056): "Based on the positive results from our pivotal program, we submitted an NDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm
- SEC Form 10-K (accession 0001933414-26-000056): "We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm

### December 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05968430 (Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." https://clinicaltrials.gov/study/NCT05968430

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: moderate to severe obstructive sleep apnea and hypertension.
- First seen 2025-08-12, last confirmed 2026-01-06.
- SEC Form 8-K (accession 0001933414-26-000002): "On January 6, 2026, the Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safety and efficacy of lorundrostat in participants with moderate to severe obstructive sleep apnea and hypertension, in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys-20260106.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000139): "•Explore-OSA Phase 2 Trial - Enrollment is complete and topline data is anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000002): "•Explore-OSA Phase 2 Trial - The Company remains on track to report topline results from the Phase 2 Explore-OSA trial in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000002/mlys202601068kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000139): "- Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341425000139/mlys2025q38kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-25-000088): "The Company anticipates reporting topline results from Explore-OSA in 1H 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys2025q28kex991.htm
- SEC Form 10-Q (accession 0001933414-25-000142): "We anticipate reporting topline results from Explore-OSA in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000142/mlys-20250930.htm
- SEC Form 10-Q (accession 0001933414-25-000090): "Additionally, the Explore-OSA trial, initiated in the first quarter of 2025, continues to enroll participants with OSA and uHTN, and we anticipate topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341425000090/mlys-20250630.htm

### March 9, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Stage: 2. Indication: hypertension.
- First seen 2026-03-09, last confirmed 2026-03-12.
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000054): "- Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000054): "•Lorundrostat New Drug Application (NDA) - Mineralys announced the U.S. Food and Drug Administration (FDA) has accepted the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs and assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm
- SEC Form 8-K (accession 0001933414-26-000048): "On March 9, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and topline results from the Company's Phase 2 Explore-OSA exploratory trial." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm
- SEC Form 8-K (accession 0001933414-26-000048): "On March 6, 2026, the FDA notified the Company that its NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs had been accepted." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm

### December 22, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: hypertension in combination with other antihypertensive drugs.
- First seen 2026-03-09, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000142): "- Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000142): "•Lorundrostat New Drug Application (NDA) — The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000112): "- PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval -" https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000112): "•Lorundrostat New Drug Application (NDA) — The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000112): "•Commercial Launch Readiness — The Company continues to advance commercial launch preparations ahead of lorundrostat's PDUFA target date of December 22, 2026 and remains on track." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000082): "- NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys2026q18kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000082): "•Lorundrostat New Drug Application (NDA) - The U.S. Food and Drug Administration (FDA) accepted the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs and assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys2026q18kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000082): "•Pre-Commercial Activities Underway - The Company is executing on its pre-commercial activities in preparation for the December 22, 2026 PDUFA target date for lorundrostat." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys2026q18kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000054): "- Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 -" https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm
- Press release filed with the SEC (EX-99) (accession 0001933414-26-000054): "•Lorundrostat New Drug Application (NDA) - Mineralys announced the U.S. Food and Drug Administration (FDA) has accepted the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs and assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm
- SEC Form 10-Q (accession 0001933414-26-000144): "The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- SEC Form 10-Q (accession 0001933414-26-000114): "The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat." https://www.sec.gov/Archives/edgar/data/1933414/000193341426000114/mlys-20260630.htm

## Same indication

- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lorundrostat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lorundrostat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lorundrostat

```bibtex
@misc{secapidev_pdufa_lorundrostat_20261116,
  title        = {Lorundrostat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lorundrostat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lorundrostat_20261116","title":"Lorundrostat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lorundrostat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
